Hypoxia Drives Tumor Immune Suppression and Immunotherapy Resistance

Описание: Presented By: Michael A. Curran, PhD

Speaker Biography: Dr. Curran received a Ph.D. in Immunology from Stanford University where he was awarded the McDevitt prize for the best graduate thesis in his year. Dr. Curran was the first recipient of the prestigious American Cancer Society Levy Fellowship to fund his post-doctoral studies in the lab of Dr. James P. Allison. While pursuing his postdoctoral studies at Memorial Sloan-Kettering Cancer Center, Dr. Curran published several influential manuscripts describing how T cell co-stimulatory pathways could be modulated in tandem to mediate immunologic rejection of melanomas in mice. Dr. Curran was the first to describe how combination blockade of the T cell co-inhibitory receptors CTLA-4 and PD-1 promoted the rejection of a majority of murine melanomas – a combination that remains the most effective FDA-approved immunotherapy. At the MD Anderson Cancer Center, Dr. Curran is an Associate Professor of Immunology and his Lab seeks to discover the underlying mechanisms of immune resistance in the “coldest” tumors, pancreatic and prostate adenocarcinoma and glioblastoma, so that rational therapeutic interventions can be developed to restore T cell infiltration and sensitivity to T cell checkpoint blockade. This research focuses on normalization of tumor oxygen metabolism to increase T cell metabolic fitness, and on pro-inflammatory activation of tumor myeloid stroma.

Webinar: Hypoxia Drives Tumor Immune Suppression and Immunotherapy Resistance

Webinar Abstract: Hypoxia is pervasive across human cancer and its association with poor outcomes and aggressive malignant phenotypes has been increasingly appreciated. Previously, we and others described how T cells are virtually absent from hypoxic zones of tumors. Serendipitously, we discovered that the hypoxia-activated prodrug (HAP) TH-302 could potently reduce hypoxia in murine models of prostate, pancreatic and head and neck cancer. With this tool, we were able to test the hypothesis that reversal of hypoxia might restore T cell infiltration and improve sensitivity to T cell checkpoint blockade in “cold” tumors. Across both transplantable and spontaneous murine models of prostate cancer, we have shown that the combination of TH-302 and antibody blockade of CTLA-4 and PD-1 synergize in curing, regressing, or controlling these tumors. With our collaborator Dr. Hong, we launched a clinical trial of the combination of TH-302 (evofosfamide) and ipilimumab (αCTLA-4) in 2017 (NCT03098160) which has revealed the potential of this combination to regress established metastatic prostate and head and neck cancers in patients, and to significantly extend progression-free survival in late stage pancreatic cancer. While TH-302 can restore tumor oxygen supply, we have observed across multiple human and murine cancers that elevated oxygen metabolism (OxPhos) at the tumor cell level metabolically cripples T cells resulting in resistance to immunotherapy. Ongoing efforts in the lab are exploring mechanisms to selectively disable tumor oxygen hyper-metabolism, as well as alternative approaches to further dampen hypoxia in cancer.

Learning Objectives:

1. Describe the impact of hypoxia on tumor immunity

2. Identify approaches for reducing tumor hypoxia

3. Describe the clinical impact of hypoxia reduction on sensitivity to CTLA-4 blockade

Earn PACE Credits:
1. Make sure you’re a registered member of LabRoots https://www.labroots.com/virtual-even...
2. Watch the webinar on YouTube or on the LabRoots Website https://www.labroots.com/webinar/keyn...
3. Click Here to get your PACE credits (Expiration date – June 02, 2023): https://www.labroots.com/credit/pace-...

LabRoots on Social:
Facebook:   / labrootsinc  
Twitter:   / labroots  
LinkedIn:   / labroots  
Instagram:   / labrootsinc  
Pinterest:   / labroots  
SnapChat: labroots_inc